4^th Microbiome Movement – Drug Development Summit

June 26-28, 2019 | Boston, MA

Returning for the fourth year, the Microbiome Movement – Drug Development Summit continues to be the industry-leading forum to help forward thinking researchers from the pharmaceutical, biotech and academic community pursue the causal role of the human microbiome in disease, to create a new generation of targeted treatments that demonstrate consistent clinical outcomes and predictable MoAs.

If you are, or would like to be, a player in the microbiome arena, this is the conference you should attend to not only hear the latest pre-clinical and clinical development from organizations developing microbiome-based therapeutics, biomarkers and diagnostics, but also make long-lasting connections that will accelerate your microbiome developments forward, and help translate this promising science into a reality for patients.

Hear from 60+ expert speakers including:

• Alison Lawton, CEO, Kaleido Biosciences
• Bernat Olle, CEO, Vedanta Biosciences
• Cathryn Nagler, Bunning Food Allergy Professor, University of Chicago
• Eric Shaff, CEO, Seres Therapeutics
• Esi Lamouse-Smith, Director, Janssen Pharmaceuticals
• Ken Blount, CSO, Rebiotix
• Mike Romanos, CEO, Microbiotica
• Ulrich Thienel, Chief Medical Officer, Finch Therapeutics Group

See the complete agenda and speaker list: https://ter.li/nefsqj

Early booking rates and group discounts are available. Visit the website to learn more: https://ter.li/1bcb5n.